UCSF spinout Kopra Bio has raised $9.1M to inject a genetically engineered virus into glioblastoma patients in a China trial.
Glioblastoma is notoriously good at evading the immune system, making it particularly resistant to immunotherapy, but now researchers may have found a …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Cambrian's experimental longevity drug mimics exercise
ChronicleBio Is Coming for Chronic Disease: Pioneering Immunologist Joins Elite Scientific Team to Translate Biological Signal into Targeted Therapeutics
Prometheus raises $12 billion in capital for artificial engineers
New York City-based startup Waypoint Bio has raised $20 million in series A financing to test multiple cell therapies in China.
Trial results for Lilly's "triple-G" drug, FDA's leadership purge leaves chaos, and more biotech news from The Readout
Yoltech Therapeutics, one of China’s most prolific gene editing companies has raised its biggest round of funding ahead of plans…
On Tuesday, Oorja Bio launched with a $30 million Series A round all from Westlake BioPartners to study a new treatment for…
Latus Bio raised $42 million as it prepares to seek FDA approval to start a clinical trial for its gene therapy for Huntington's…
A second shot at gene therapy for Huntington's, China's tightening grip on pharma supply chains, and more Readout biotech updates
